Oral Mucositis Clinical Trial
Official title:
A Phase 1b, Multi-center, Single Blinded, Placebo-controlled, Sequential Dose Escalation Study to Assess the Safety and Tolerability of Topically Applied AG013 in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck
The purpose of this study is to assess the safety and tolerability of AG013 (genetically modified L. lactis bacteria engineered to secrete human Trefoil Factor 1), and to explore the ability of AG013 to attenuate the course and severity of oral mucositis (OM) in subjects receiving induction chemotherapy for the treatment of head and neck cancer.
The purpose of this study is to investigate the safety and tolerability of AG013 in subjects
who are at risk for oral mucositis (OM) and to assess clinical efficacy of AG013 in the
reduction of signs and symptoms of OM in patients receiving induction chemotherapy for the
treatment of their head and neck cancer.
AG013 is made up of genetically modified (GM) bacteria called Lactococcus lactis (L.
lactis). Wild type L. lactis are commonly used to produce dairy products including cheeses
and milk. To make AG013, the DNA of L. lactis has been changed in the laboratory to secrete
a protein called human Trefoil Factor 1 (hTFF1). hTFF1 is normally secreted in saliva and
intestines. Trefoil factors have been shown to be important in protecting and healing
mucosal tissues, such as the tissue in the mouth, when these tissues are damaged by cancer
therapies such as chemotherapy and radiation therapy.
The proposed Phase 1b clinical trial will enroll subjects with head and neck cancer who
develop OM during their first cycle of treatment with induction chemotherapy. OM is a
painful, common toxicity of many forms of drug and radiation therapy used for the treatment
of cancer. Subjects with OM get soreness, irritation, and ulcers in the mouth and may have
difficulties eating, drinking or swallowing as a result of their cancer treatment.
During the second cycle of induction chemotherapy, eligible subjects will receive AG013 or
placebo for 14 consecutive days at a frequency of one rinse, three rinses or six rinses per
day (sequential dose escalation design).
At least 21 subjects will be enrolled in the study. For each of the three daily dose levels,
5 subjects will be assigned to AG013 (n=5) and 2 subjects will be assigned to placebo (n=2).
Throughout the study, safety will be monitored by collecting and recording Adverse Events,
laboratory assessments and the presence of sAGX0085 bacteria in blood.
An independent Data Safety Monitoring Board (DSMB) will be constituted before the enrollment
of subjects in order to review safety data from each enrollment group.
;
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02229136 -
Miracle Mouthwash Plus Hydrocortisone vs Prednisolone Mouth Rinse for Mouth Sores Caused by Everolimus
|
Phase 2 | |
Terminated |
NCT03843554 -
Commensal Oral Microbiota in Head and Neck Cancer
|
N/A | |
Enrolling by invitation |
NCT02662374 -
Oral Hygiene Regimen in Patients on HCT
|
Phase 4 | |
Completed |
NCT00756951 -
Dose Ranging Study to Assess the Safety and Efficacy of SCV-07 for the Delay to Onset of Severe Oral Mucositis in Patients Receiving Chemoradiation Therapy for Head and Neck Cancer
|
Phase 2 | |
Completed |
NCT00701688 -
Dose Escalation Study Of Palifermin in Pediatric Research Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 1 | |
Not yet recruiting |
NCT05059613 -
Thalidomide With or Without Probiotics in Radioactive Oral Mucositis
|
N/A | |
Completed |
NCT04440930 -
White Tea for Prevention of Chemotherapy Induced Mucositis
|
N/A | |
Completed |
NCT05705622 -
The Effect of Nursing Education on Oral Mucositis in Bone Marrow Transplant Patients
|
N/A | |
Completed |
NCT02399228 -
A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of Oral Mucositis
|
Phase 2 | |
Withdrawn |
NCT02589860 -
Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell Transplant
|
||
Active, not recruiting |
NCT01772706 -
Laser Mucite ORL : Effectiveness of Laser Therapy for Mucositis Induced by a Radio-chemotherapy in Head and Neck Cancer
|
N/A | |
Enrolling by invitation |
NCT06122636 -
Efficacy of a Probiotic and Microbiological Analysis on Oral Complications Induced by Antineoplastic Therapies in Patients With HNC
|
N/A | |
Completed |
NCT03689712 -
ROMAN: Phase 3 Trial Investigating the Effects of GC4419 on Radiation Induced Oral Mucositis in Head/Neck Cancer Patients
|
Phase 3 | |
Terminated |
NCT02539342 -
Caphosol Study: Prevention of Oral Mucositis in Children, Adolescents and Young Adults Receiving Chemotherapy
|
Phase 3 | |
Completed |
NCT02555501 -
Oral Mucositis and Laser Therapy Associated With Photodynamic Therapy
|
Phase 3 | |
Completed |
NCT01789658 -
Cryotherapy for Prevention of Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation
|
N/A | |
Completed |
NCT00790322 -
Efficacy and Safety Study of SBG vs Placebo in Head and Neck Cancer Patients Undergoing Radiation Therapy
|
Phase 3 | |
Recruiting |
NCT00549952 -
Observational Study of Anti-Cancer Therapy Induced Oral Mucositis in Korean Cancer Patients
|
N/A | |
Completed |
NCT00289003 -
The Protective Effect of Soluble Beta-1,3/1,6-Glucan Compared to Placebo in Oral Mucositis in Head and Neck Cancer Patients
|
Phase 2 | |
Completed |
NCT05635929 -
Oral Mucositis and Quality of Life With a Mucosa Topical Composition in Head & Neck Cancer Patients.
|
N/A |